KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Operating Leases (2019 - 2025)

TherapeuticsMD's Operating Leases history spans 7 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 28.61% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $5.1 million, down 28.61%, while the annual FY2025 figure was $5.1 million, 28.61% down from the prior year.
  • Operating Leases reached $5.1 million in Q4 2025 per TXMD's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.5 million in Q1 2021 to a low of $5.1 million in Q4 2025.
  • Average Operating Leases over 5 years is $7.1 million, with a median of $7.3 million recorded in 2022.
  • Peak YoY movement for Operating Leases: increased 8.63% in 2023, then decreased 28.61% in 2025.
  • A 5-year view of Operating Leases shows it stood at $8.1 million in 2021, then fell by 8.61% to $7.4 million in 2022, then rose by 8.63% to $8.0 million in 2023, then decreased by 10.37% to $7.2 million in 2024, then fell by 28.61% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Operating Leases are $5.1 million (Q4 2025), $5.4 million (Q3 2025), and $5.7 million (Q2 2025).